RA Capital Management 13F holdings, Q1 2020
Holdings as of March 31, 2020 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 48 US equity positions worth $3.2bn in its Q1 2020 13F filing. The largest position was ASND at 17.5% of the reported book, followed by RA PHARMACEUTICALS INC and CHEMOCENTRYX INC. Against the Q4 2019 filing, it opened 18 new positions, added to 15 and reduced 4 among the top 48 holdings.
What did RA Capital Management own in Q1 2020? Top 48 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2019 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 17.5% | $553.5m | 4,914,955 | 17% | added |
| 2 | RA PHARMACEUTICALS INC | 7.4% | $233.2m | 4,858,260 | 0% | held | |
| 3 | CHEMOCENTRYX INC | 5.3% | $167.8m | 4,176,910 | 31% | added | |
| 4 | ARVN ARVINAS INC | Healthcare | 4.7% | $148.0m | 3,672,872 | 0% | held |
| 5 | ZOGENIX INC | 4.1% | $130.5m | 5,275,538 | 133% | added | |
| 6 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 3.5% | $112.0m | 1,904,094 | 418% | added |
| 7 | EIDOS THERAPEUTICS INC | 3.3% | $105.9m | 2,162,671 | 0% | held | |
| 8 | TGTX TG THERAPEUTICS INC | Healthcare | 3.2% | $102.2m | 10,387,411 | 5% | added |
| 9 | SATSUMA PHARMACEUTICALS INC | 3.2% | $100.8m | 4,681,858 | 0% | held | |
| 10 | ALEC ALECTOR INC | Healthcare | 3.1% | $99.6m | 4,127,348 | 313% | added |
| 11 | PHAT PHATHOM PHARMACEUTICALS INC | 3.0% | $95.7m | 3,707,408 | 2% | added | |
| 12 | KALA PHARMACEUTICALS INC | 3.0% | $95.6m | 10,874,613 | 140% | added | |
| 13 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.6% | $82.5m | 5,422,312 | 0% | held |
| 14 | 89BIO INC | 2.5% | $79.8m | 3,161,214 | 0% | held | |
| 15 | EXEL EXELIXIS INC | Healthcare | 2.5% | $77.9m | 4,524,961 | – | new |
| 16 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 2.3% | $72.9m | 7,775,207 | 0% | held |
| 17 | ADVERUM BIOTECHNOLOGIES INC | 2.2% | $71.1m | 7,272,714 | – | new | |
| 18 | MNTA MOMENTA PHARMACEUTICALS INC | 2.2% | $68.9m | 2,531,445 | 75% | added | |
| 19 | BLACK DIAMOND THERAPEUTICS INC | 2.0% | $64.6m | 2,589,904 | – | new | |
| 20 | RETROPHIN INC | 1.9% | $60.8m | 4,166,453 | -2% | reduced | |
| 21 | ORCHARD THERAPEUTICS PLC | 1.8% | $57.0m | 10,364,658 | 62% | added | |
| 22 | IGM BIOSCIENCES INC | 1.7% | $55.2m | 982,723 | 0% | held | |
| 23 | VSTM VERASTEM INC | Healthcare | 1.6% | $49.1m | 18,604,651 | – | new |
| 24 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.5% | $47.1m | 1,379,988 | 81% | added |
| 25 | GILD GILEAD SCIENCES INC | Healthcare | 1.3% | $41.0m | 548,000 | – | new |
| 26 | PREVAIL THERAPEUTICS INC | 1.2% | $39.5m | 3,240,534 | -4% | reduced | |
| 27 | ARDX ARDELYX INC | Healthcare | 1.2% | $36.5m | 6,416,684 | 20% | added |
| 28 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 1.1% | $34.7m | 1,165,184 | – | new |
| 29 | ADAPY ADAPTIMMUNE THERAPEUTICS PLC | Healthcare | 1.1% | $34.1m | 12,541,888 | – | new |
| 30 | CRINETICS PHARMACEUTICALS INC | 0.9% | $28.8m | 1,961,209 | 5% | added | |
| 31 | SCPHARMACEUTICALS INC | 0.8% | $26.0m | 3,518,998 | 8% | added | |
| 32 | TRILLIUM THERAPEUTICS INC | 0.8% | $25.7m | 6,361,446 | – | new | |
| 33 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.8% | $25.6m | 1,119,963 | 0% | held |
| 34 | IMARA INC | 0.7% | $23.3m | 1,454,348 | – | new | |
| 35 | CGEN COMPUGEN LTD | Healthcare | 0.7% | $21.5m | 2,957,434 | – | new |
| 36 | IMMUNOGEN INC | 0.6% | $17.6m | 5,166,303 | – | new | |
| 37 | NVCR NOVOCURE LTD | Healthcare | 0.6% | $17.4m | 259,099 | – | new |
| 38 | CONCERT PHARMACEUTICALS INC | 0.5% | $16.4m | 1,858,474 | – | new | |
| 39 | SLDB SOLID BIOSCIENCES INC | 0.3% | $10.9m | 4,571,164 | 0% | held | |
| 40 | GALERA THERAPEUTICS INC | 0.3% | $8.5m | 893,115 | -15% | reduced | |
| 41 | XFOR X4 PHARMACEUTICALS INC | 0.2% | $6.0m | 602,274 | 123% | added | |
| 42 | PASG PASSAGE BIO INC | 0.2% | $5.1m | 322,630 | – | new | |
| 43 | UNIQURE NV | 0.1% | $3.9m | 82,180 | – | new | |
| 44 | ESSA PHARMA INC | 0.1% | $3.8m | 959,300 | -4% | reduced | |
| 45 | PORTOLA PHARMACEUTICALS INC | 0.1% | $3.1m | 429,399 | 0% | held | |
| 46 | RNAC SELECTA BIOSCIENCES INC | Healthcare | 0.1% | $2.1m | 870,633 | – | new |
| 47 | INSM INSMED INC | Healthcare | 0.0% | $1.4m | 87,405 | – | new |
| 48 | VCEL VERICEL CORP | Healthcare | 0.0% | $917.0k | 100,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.